Literature DB >> 20297872

Early diagnosis of Parkinson's disease: recommendations from diagnostic clinical guidelines.

Rajesh Pahwa1, Kelly E Lyons.   

Abstract

Therapeutic options for Parkinson's disease (PD) are currently limited to symptomatic agents. Levodopa is the most efficacious treatment; however, higher doses and long-term use are associated with adverse effects such as motor fluctuations and dyskinesia. Early treatment of PD with other agents such as dopamine agonists and monoamine oxidase type B inhibitors can provide symptomatic benefit and delay initiation of levodopa therapy. Early treatment of PD is contingent upon early and accurate diagnosis of the disease, which can be challenging because there are no biomarkers or neuroimaging or other clinical tests available to confirm the diagnosis. PD diagnosis is currently based on the presence or absence of various clinical features and the experience of the treating physician. A definitive diagnosis can be made only after autopsy. Moreover, the signs and symptoms present in early PD can resemble those of a number of other movement disorders, particularly other forms of parkinsonism, such as multiple system atrophy, drug-induced parkinsonism, and vascular parkinsonism, as well as diffuse Lewy body disease and essential tremor. Nevertheless, diagnosis of PD based on clinical features and response to antiparkinsonian medication can be achieved with a fairly high level of accuracy, particularly when made by a physician specializing in movement disorders. This article reviews and summarizes published recommendations for the clinical diagnosis of PD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20297872

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  21 in total

1.  Evaluating the Cost-Effectiveness of an Early Detection of Parkinson's Disease through Innovative Technology.

Authors:  David A Munoz; Mehmet Serdar Kilinc; Harriet B Nembhard; Conrad Tucker; Xuemei Huang
Journal:  Eng Econ       Date:  2017-03-22       Impact factor: 0.861

2.  Evaluation of Parkinson disease and Alzheimer disease with the use of neuromelanin MR imaging and (123)I-metaiodobenzylguanidine scintigraphy.

Authors:  F Miyoshi; T Ogawa; S-i Kitao; M Kitayama; Y Shinohara; M Takasugi; S Fujii; T Kaminou
Journal:  AJNR Am J Neuroradiol       Date:  2013-06-06       Impact factor: 3.825

Review 3.  Targeting progressive neuroaxonal injury: lessons from multiple sclerosis.

Authors:  Amit Bar-Or; Peter Rieckmann; Anthony Traboulsee; V Wee Yong
Journal:  CNS Drugs       Date:  2011-09-01       Impact factor: 5.749

4.  [123I]Metaiodobenzylguanidine (MIBG) Cardiac Scintigraphy and Automated Classification Techniques in Parkinsonian Disorders.

Authors:  Susanna Nuvoli; Angela Spanu; Mario Luca Fravolini; Francesco Bianconi; Silvia Cascianelli; Giuseppe Madeddu; Barbara Palumbo
Journal:  Mol Imaging Biol       Date:  2020-06       Impact factor: 3.488

Review 5.  Role of Neuroimaging on Differentiation of Parkinson's Disease and Its Related Diseases.

Authors:  Toshihide Ogawa; Shinya Fujii; Keita Kuya; Shin-Ichiro Kitao; Yuki Shinohara; Mana Ishibashi; Yoshio Tanabe
Journal:  Yonago Acta Med       Date:  2018-09-26       Impact factor: 1.641

6.  Parkinson's Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis.

Authors:  George DeMaagd; Ashok Philip
Journal:  P T       Date:  2015-08

Review 7.  Economic Evaluation of Interventions in Parkinson's Disease: A Systematic Literature Review.

Authors:  Nafsika Afentou; Johan Jarl; Ulf-G Gerdtham; Sanjib Saha
Journal:  Mov Disord Clin Pract       Date:  2019-04-11

8.  Slowed saccades and increased square wave jerks in essential tremor.

Authors:  George T Gitchel; Paul A Wetzel; Mark S Baron
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2013-09-03

Review 9.  The role of molecular imaging in the diagnosis and management of neuropsychiatric disorders.

Authors:  Lie-Hang Shen; Yu-Chin Tseng; Mei-Hsiu Liao; Ying-Kai Fu
Journal:  J Biomed Biotechnol       Date:  2011-03-22

10.  Parkinson's disease patient-specific neuronal networks carrying the LRRK2 G2019S mutation unveil early functional alterations that predate neurodegeneration.

Authors:  G Carola; D Malagarriga; C Calatayud; M Pons-Espinal; L Blasco-Agell; Y Richaud-Patin; I Fernandez-Carasa; V Baruffi; S Beltramone; E Molina; P Dell'Era; J J Toledo-Aral; E Tolosa; A R Muotri; J Garcia Ojalvo; J Soriano; A Raya; A Consiglio
Journal:  NPJ Parkinsons Dis       Date:  2021-07-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.